Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7929733 | 0.88 | NR1I2 (0.39) | TSHRNR1I2 | |
| SCHEMBL20090854 | 0.87 | RAPGEF4 (0.33) | — | |
| SCHEMBL12646232 | 0.86 | TSHR (0.42) | TSHRESR1ESR2MEN1MAPT | |
| SCHEMBL7835263 | 0.83 | OPRM1 (0.34) | TSHRESR1ESR2 | |
| SCHEMBL19278380 | 0.82 | MEN1 (0.34) | TSHRESR1ESR2MEN1KMT2A | |
| SCHEMBL20372814 | 0.80 | OPRM1 (0.43) | — | |
| SCHEMBL16770710 | 0.80 | TSHR (0.36) | TSHRESR1ESR2MEN1MAPT | |
| SCHEMBL16771268 | 0.80 | TSHR (0.36) | TSHRESR1ESR2MEN1MAPT | |
| SCHEMBL26169680 | 0.79 | P2RX7 (0.33) | — | |
| SCHEMBL24597837 | 0.78 | ESR1 (0.44) | TSHRESR1ESR2MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10350208-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ROIVANT SCIENCES GMBH (CH) | 2019-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10350208-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | TSHR 1218/4885ESR1 3323/4885ESR2 2059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.